Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 24,09:00-12:00
Vaccine Innovation & Global Expansion Session
Stay tuned
Meeting Planner
Jeffrey Zhang:President, Vaccine Division, Fosun Pharma
09:00-09:20 Engine Restructuring: The mRNA Drug R&D Revolution Driven by AI and Automation Technologies
Bo Ying:General Manager, Fosun Vaccines
09:20-09:40 AI-Empowered Incubation of Novel Multivalent and Multi-combination Vaccines
Jian Hou:CEO, XYnZ Biologics Co., Ltd.
09:40-10:00 Breakthrough Directions for Innovative Pneumococcal Vaccines
Tao Zhu:Director & CSO, CanSinoBIO
10:00-10:20 Formation and Evolution of China’s mRNA Platform Technology: From COVID-19 Vaccines to Next-Generation Therapeutic Systems
Jinzhong Lin:Professor, mRNA Drug R&D Center, Fudan University; Chairman, RNAcure Biopharma
10:20-10:40 AI Meets Underlying mRNA Technology at EnCureGen Pharma
Aimin Hui:Founder, Chairman & CEO, EnCureGen Pharma
10:40-11:00 Global Commercial Compliance Perspective: Quality Control Management for Vaccine Global Expansion Supported by Filtration Processes
Hong Wang:Head of Product, LePure Biotech
11:00-11:20 AI-Driven Development of Personalized Peptide Neoantigen Vaccines for Pancreatic Cancer
Landian Hu:Founder, Chairman & CEO, Anda Biopharma
11:00-12:00 Roundtable: Chinese Vaccine Innovation & Global Overseas Expansion
Sam Liao (Moderator):General Manager, NovaStream Biotech Co., Ltd.
Jeffrey Zhang:President, Vaccine Division, Fosun Pharma
Shaozhong Dong:Vice Chairman Walvax Biotechnology Co. LTD.
Weining Meng:Deputy General Manager & Head of International Business, Sinovac Biotech